PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma Sets Gold Standard As Supplier of World's First USP-NF Compliant Recombinant - Novozymes Biopharma sets gold standard as supplier of World's first USP-NF Compliant Recombinant Human Albumins
Novozymes Biopharma Sets Gold Standard As Supplier of World's First USP-NF Compliant Recombinant

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2009/05/01 - Novozymes Biopharma sets gold standard as supplier of World's first USP-NF Compliant Recombinant Human Albumins.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes, the world leader in bioinnovation, today announced that its Recombumin and albucult products are the first to comply with the new excipient monograph standard for recombinant human albumin, published in the United States Pharmacopoeia - National Formulary (USP-NF). The monograph was first published in November 2008 and became official on 1st May 2009. As these products comply with the monograph, their use eases the regulatory process for customers and sets the industry benchmark for recombinant human albumin.

Recombumin offers the stabilising and formulation benefits of human derived albumin in a GMP compliant and regulatory friendly package. Derived from Novozymes' proprietary yeast expression technology, it is the world's leading animal-free, commercially available recombinant human albumin for use in the manufacture of licensed and developmental human therapeutics in the US and European markets. Albucult is also a yeast-derived recombinant albumin, targeted for use in specialised cell culture and as a bulk drug manufacturing raw material, such as in peptide or small molecule drug chemical coupling for delivery or half-life extension.

Wayne Prestwood, Principal Regulatory Associate at Novozymes Biopharma comments, "We are delighted to be setting the gold standard with our Recombumin and albucult products by being the first to comply with the new monograph. This is of significant benefit to our customers, providing peace of mind whilst facilitating regulatory agency review and approval."

The monograph refers to recombinant human albumin as "rAlbumin Human NF" listed as a "sterile vehicle" meaning that it is intended for injection into humans alongside the active ingredient, and as such needs to be of the highest safety and quality.

Novozymes Biopharma offers a range of technologies and animal-free recombinant supplements and ingredients. Its portfolio of biological solutions includes albumin fusion technology (albufuse™) and baker's yeast-based expression technology using its proprietary Saccharomyces cerevisiae strains in a system that is a proven option for high yielding protein production. The company manufactures a range of recombinant proteins for industrial cell culture, bulk drug manufacturing and protein drug formulation.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.
Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Press and media:
Johan Melchior, T: (direct): +45 4446 0690 - T: (mobile): +45 3077 0690
René Tronborg, T: (direct): +45 4446 2274 - T: (mobile): +45 3077 2274
Paige Donnelly (USA), T: (direct): +1 919 494 3209 - T: (mobile): +1 919 218 4501

Investor relations:
Camilla Kinch Jensen, T: (direct): +45 4446 0852 - T: (mobile): +45 3077 0852
Tobias Bjørklund (USA), T: (direct): +1 919 494 3483 - T: (mobile): +1 919 649 2565

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Sets Gold Standard As Supplier of World's First USP-NF Compliant Recombinant

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Fiona Robinson 
+44 1477 539539 SYKE[.]novozymes.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  MagLar, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)